Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies

American Journal of Epidemiology

Volumn 185, Issue 2, 2017, Pages 86-95

  Brenner, Darren R ^a   Fanidi, Anouar ^a   Grankvist, Kjell ^a   Muller, David C ^a   Brennan, Paul ^a   Manjer, Jonas ^a   Byrnes, Graham ^a   Hodge, Allison ^a   Severi, Gianluca ^a   Giles, Graham G ^a   Johansson, Mikael ^a   Johansson, Mattias ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cohort studies; Cytokines; Inflammation; Lung neoplasms; Risk factors

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR MARKER;

CANCER; CARCINOGEN; COHORT ANALYSIS; CONCENTRATION (COMPOSITION); HEALTH RISK; PUBLIC HEALTH; SERUM; SMOKING; TUMOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SMOKING; BLOOD; LUNG NEOPLASMS; MIDDLE AGED; RISK FACTOR; SOCIOECONOMICS; STATISTICAL MODEL;

AUSTRALIA; MELBOURNE; SWEDEN; VICTORIA [AUSTRALIA];

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS;

EID: 85021161057     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kww159     Document Type: Article

References (22)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008; 8(4):605-615.
3. Brenner DR, Scherer D, Muir K, et al. A review of the application of inflammatory biomarkers in epidemiologiccancer research. Cancer Epidemiol Biomarkers Prev. 2014; 23(9):1729-1751.
4. Zhou X, Fragala MS, McElhaney JE, et al. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13(5):541-547.
5. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(suppl 1):i104-i108.
6. Zhou B, Liu J, Wang ZM, et al. C-reactive protein, interleukin 6 and lung cancer risk: A meta-analysis. PLoS One. 2012;7(8):e43075.
7. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14): 1112-1122.
8. Shiels MS, Pfeiffer RM, Hildesheim A, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013;105(24):1871-1880.
9. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-1081.
10. Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ. 2002;156:69-70.
11. Muller DC, Baglietto L, Manning JT, et al. Second to fourth digit ratio (2D:4D), breast cancer risk factors, and breast cancer risk: A prospective cohort study. Br J Cancer. 2012; 107(9):1631-1636.
12. Hallmans G, Agren A, Johansson G, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions. Scand J Public Health Suppl. 2003;61:18-24.
13. Berglund G, Elmstahl S, Janzon L, et al. The Malmö Diet and Cancer Study. Design and feasibility. J Intern Med. 1993;233(1):45-51.
14. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106(11):1-8.
15. Liu J, Liang Q, Frost-Pineda K, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1760-1769.
16. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the Health Aging and Body Composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-2418.
17. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
18. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-1183.
19. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
20. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245-254.
21. Shiels MS, Katki HA, Hildesheim A, et al. Circulating inflammation markers, risk of lung cancer, and utility for risk stratification. J Natl Cancer Inst. 2015;107(10):1-9.
22. Sin DD, Man SF, McWilliams A, et al. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med. 2006;173(5):535-539.